Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report), Twist...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Scholar Rock Holding (($SRRK)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of Scholar Rock...

Scholar Rock’s Earnings Call: Optimism Amid Regulatory Challenges

Traders will find all the latest earnings reports, economic data, and deals leading the stock market on Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Scholar Rock stock was on the rise Friday despite a lackluster earnings report.


Current Quarter	$-0.87	Next Quarter	$-0.84
Current Year	$-3.33	Next Year	$-2.73
QoQ Growth	+3.4%	YoY Growth	+18.0%
3Y EPS CAGR	+11.7%	Target Price	$46.55
Consensus	Buy	Upside	+15.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$40.21	+5.76%	2.08M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$40.21	+5.8%	2.08M
3
4
5
6

SRRK

SRRK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel